Catheter Precision Financials
Catheter Precision (VTAK) reported $819K in revenue for fiscal year 2025, up 95.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Tiny revenue means Catheter Precision still runs on external funding, and liquidity tightened sharply despite lower cash burn.
Operating cash use fell from$20.6M in FY2023 to$8.3M in FY2025, so the company became less cash-hungry. But financing inflows also slipped to$5.3M while cash ended at$88K , showing that lower burn still did not produce liquidity because outside funding no longer closed the gap.
FY2025 revenue of
A gross margin of
Financial Health Signals
Catheter Precision does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Catheter Precision scores -31.88, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($805K) relative to total liabilities ($9.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Catheter Precision passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Catheter Precision reported a net loss of $17.2M while operations used $8.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Catheter Precision generated $819K in revenue in fiscal year 2025. This represents an increase of 95.0% from the prior year.
Catheter Precision's EBITDA was -$19.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 108.3% from the prior year.
Catheter Precision reported -$17.2M in net income in fiscal year 2025. This represents a decrease of 3.2% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Catheter Precision recorded an outflow of $8.3M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 11.0% from the prior year.
Catheter Precision held $88K in cash against $3.1M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Catheter Precision's gross margin was 92.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 2.3 percentage points from the prior year.
Catheter Precision's ROE was -243.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 102.0 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Catheter Precision invested $862K in research and development in fiscal year 2025. This represents an increase of 216.9% from the prior year.
Catheter Precision invested $17K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 74.6% from the prior year.
Not reported for fiscal year 2025.
VTAK Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $819K+95.0% | $420K-5.0% | $442K+3057.1% | $14K-36.4% | $22K-91.5% | $259K-96.4% | $7.2M+15.1% | $6.3M+6.6% | $5.9M |
| Cost of Revenue | $94K | $63K+50.0% | $42K+40.0% | $30K-81.4% | $161K-89.7% | $1.6M-28.2% | $2.2M-75.5% | $8.8M+110.4% | $4.2M+1.0% | $4.2M |
| Gross Profit | $1.0M | $756K+100.0% | $378K-8.3% | $412K+380.3% | -$147K+90.4% | -$1.5M+19.6% | -$1.9M-15.9% | -$1.7M-180.5% | $2.1M+20.3% | $1.7M |
| R&D Expenses | $908K | $862K+216.9% | $272K-42.7% | $475K-92.6% | $6.4M-47.8% | $12.3M+36.8% | $9.0M+97.7% | $4.5M+63.2% | $2.8M-38.6% | $4.5M |
| SG&A Expenses | $11.1M | $12.1M+6.4% | $11.3M-33.7% | $17.1M+5.4% | $16.3M+5.0% | $15.5M-36.9% | $24.5M-52.4% | $51.5M+69.4% | $30.4M+103.6% | $14.9M |
| Operating Income | -$19.9M | -$21.1M-88.1% | -$11.2M+85.6% | -$78.1M-189.7% | -$27.0M+7.9% | -$29.3M+17.3% | -$35.4M+38.7% | -$57.7M-85.3% | -$31.2M-75.5% | -$17.8M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | $108K-56.8% | $250K+1685.7% | $14K+250.0% | $4K |
| Income Tax | -$1.3M | -$1.8M-157.6% | $3.1M | $0-100.0% | $3K-25.0% | $4K-42.9% | $7K-53.3% | $15K+50.0% | $10K+900.0% | $1K |
| Net Income | -$14.8M | -$17.2M-3.2% | -$16.6M+76.4% | -$70.6M-162.7% | -$26.9M-7.2% | -$25.1M+30.4% | -$36.0M+36.7% | -$57.0M-84.7% | -$30.8M-73.6% | -$17.8M |
| EPS (Diluted) | — | N/A | N/A | N/A | -$25.98 | -$248.22 | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
VTAK Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $15.9M-42.9% | $27.8M-9.6% | $30.7M+82.6% | $16.8M-20.0% | $21.0M-37.1% | $33.4M-24.1% | $44.1M-40.5% | $74.0M+557.0% | $11.3M |
| Current Assets | $390K-88.2% | $3.3M-20.9% | $4.2M-75.3% | $16.8M-1.5% | $17.1M-38.1% | $27.6M-23.3% | $36.0M-48.0% | $69.2M+589.4% | $10.0M |
| Cash & Equivalents | $88K-96.9% | $2.9M-19.4% | $3.6M-77.5% | $15.9M+5.4% | $15.0M-37.1% | $23.9M+63.9% | $14.6M-77.3% | $64.3M+680.8% | $8.2M |
| Inventory | $86K+160.6% | $33K-25.0% | $44K | $0-100.0% | $986K+12.4% | $877K-68.4% | $2.8M+32.4% | $2.1M+75.3% | $1.2M |
| Accounts Receivable | $155K+121.4% | $70K-48.9% | $137K | $0-100.0% | $21K-12.5% | $24K-96.9% | $786K-40.5% | $1.3M+155.3% | $517K |
| Goodwill | $0 | N/A | $0 | $0 | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $9.2M-42.5% | $16.0M+67.8% | $9.5M+26.0% | $7.6M+2.8% | $7.4M-40.0% | $12.3M+12.4% | $10.9M+49.1% | $7.3M-61.2% | $18.9M |
| Current Liabilities | $3.9M+75.2% | $2.2M-9.8% | $2.5M-67.4% | $7.6M+40.6% | $5.4M-30.6% | $7.8M+13.9% | $6.8M+14.5% | $6.0M+126.0% | $2.6M |
| Long-Term Debt | $3.1M | N/A | N/A | N/A | N/A | N/A | $558K-34.4% | $850K | N/A |
| Total Equity | $7.1M-40.0% | $11.8M-44.5% | $21.2M+128.9% | $9.3M-32.3% | $13.7M-35.3% | $21.1M-36.2% | $33.1M-50.3% | $66.7M+976.2% | -$7.6M |
| Retained Earnings | -$309.5M-5.9% | -$292.4M-6.0% | -$275.7M-34.4% | -$205.1M-15.1% | -$178.3M-16.4% | -$153.2M-30.8% | -$117.2M-94.5% | -$60.2M-104.9% | -$29.4M |
VTAK Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$8.8M | -$8.3M+10.5% | -$9.3M+55.0% | -$20.6M+8.6% | -$22.6M+18.3% | -$27.6M+2.4% | -$28.3M+14.7% | -$33.2M-79.2% | -$18.5M-235.1% | -$5.5M |
| Capital Expenditures | $13K | $17K-74.6% | $67K-11.8% | $76K+347.1% | $17K-93.6% | $265K+295.5% | $67K-75.0% | $268K-54.0% | $582K+6.4% | $547K |
| Free Cash Flow | -$8.8M | -$8.3M+11.0% | -$9.3M+54.9% | -$20.7M+8.4% | -$22.6M+19.0% | -$27.9M+1.7% | -$28.4M+15.2% | -$33.4M-75.2% | -$19.1M-214.5% | -$6.1M |
| Investing Cash Flow | -$1.1M | $167K+349.3% | -$67K-9.8% | -$61K-390.5% | $21K-99.4% | $3.8M-76.1% | $15.9M+199.4% | -$16.0M-2654.6% | -$582K-6.4% | -$547K |
| Financing Cash Flow | $9.9M | $5.3M-38.2% | $8.6M+3.1% | $8.4M-64.1% | $23.4M+56.1% | $15.0M-31.0% | $21.7M+4224.1% | -$526K-100.7% | $75.2M+623.7% | $10.4M |
| Dividends Paid | N/A | N/A | N/A | $800K | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Share Buybacks.
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
VTAK Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 92.3%+2.3pp | 90.0%-3.2pp | 93.2% | -1050.0% | -6990.9% | -738.6% | -22.9%-55.7pp | 32.8%+3.7pp | 29.0% |
| Operating Margin | -2581.6% | -2676.9% | -17674.0% | -192578.6% | -133027.3% | -13668.3% | -801.9% | -498.0% | -302.6% |
| Net Margin | -2098.0% | -3962.6% | -15966.5% | -191892.9% | -113954.5% | -13917.0% | -791.2% | -492.8% | -302.6% |
| Return on Equity | -243.6%-102.0pp | -141.6%+191.4pp | -333.0%-42.9pp | -290.1%-106.8pp | -183.3%-12.9pp | -170.4%+1.4pp | -171.8%-125.6pp | -46.2% | N/A |
| Return on Assets | -108.3%-48.4pp | -59.9%+169.7pp | -229.6%-70.0pp | -159.6%-40.4pp | -119.1%-11.3pp | -107.8%+21.4pp | -129.2%-87.6pp | -41.6%+116.0pp | -157.6% |
| Current Ratio | 0.10-1.4x | 1.48-0.2x | 1.68-0.5x | 2.22-0.9x | 3.17-0.4x | 3.56-1.7x | 5.28-6.4x | 11.64+7.8x | 3.81 |
| Debt-to-Equity | 0.44-0.9x | 1.36+0.9x | 0.45-0.4x | 0.82+0.3x | 0.540.0x | 0.58+0.6x | 0.020.0x | 0.01 | N/A |
| FCF Margin | -1015.0% | -2223.3% | -4682.1% | -161321.4% | -126772.7% | -10954.0% | -464.5% | -305.1% | -103.4% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Note: The current ratio is below 1.0 (0.10), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Catheter Precision Ranks
Frequently Asked Questions
What is Catheter Precision's annual revenue?
Catheter Precision (VTAK) reported $819K in total revenue for fiscal year 2025. This represents a 95.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Catheter Precision's revenue growing?
Catheter Precision (VTAK) revenue grew by 95.0% year-over-year, from $420K to $819K in fiscal year 2025.
Is Catheter Precision profitable?
No, Catheter Precision (VTAK) reported a net income of -$17.2M in fiscal year 2025.
What is Catheter Precision's EBITDA?
Catheter Precision (VTAK) had EBITDA of -$19.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Catheter Precision have?
As of fiscal year 2025, Catheter Precision (VTAK) had $88K in cash and equivalents against $3.1M in long-term debt.
What is Catheter Precision's gross margin?
Catheter Precision (VTAK) had a gross margin of 92.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Catheter Precision's return on equity (ROE)?
Catheter Precision (VTAK) has a return on equity of -243.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Catheter Precision's free cash flow?
Catheter Precision (VTAK) recorded an outflow of $8.3M in free cash flow during fiscal year 2025. This represents a 11.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Catheter Precision's operating cash flow?
Catheter Precision (VTAK) recorded an outflow of $8.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Catheter Precision's total assets?
Catheter Precision (VTAK) had $15.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Catheter Precision's capital expenditures?
Catheter Precision (VTAK) invested $17K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Catheter Precision spend on research and development?
Catheter Precision (VTAK) invested $862K in research and development during fiscal year 2025.
What is Catheter Precision's current ratio?
Catheter Precision (VTAK) had a current ratio of 0.10 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Catheter Precision's debt-to-equity ratio?
Catheter Precision (VTAK) had a debt-to-equity ratio of 0.44 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Catheter Precision's return on assets (ROA)?
Catheter Precision (VTAK) had a return on assets of -108.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Catheter Precision's cash runway?
Based on fiscal year 2025 data, Catheter Precision (VTAK) had $88K in cash against an annual operating cash burn of $8.3M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Catheter Precision's Altman Z-Score?
Catheter Precision (VTAK) has an Altman Z-Score of -31.88, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Catheter Precision's Piotroski F-Score?
Catheter Precision (VTAK) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Catheter Precision's earnings high quality?
Catheter Precision (VTAK) reported a net loss of $17.2M while operations used $8.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.